Evidence map›Paper›PMID 30355503›Full record

ArticleCell reports2018

KMT2B Is Selectively Required for Neuronal Transdifferentiation, and Its Loss Exposes Dystonia Candidate Genes.

Giulia Barbagiovanni, Pierre-Luc Germain, Michael Zech, Sina Atashpaz, Pietro Lo Riso, Agnieszka D'Antonio-Chronowska, Erika Tenderini, Massimiliano Caiazzo, Sylvia Boesch, Robert Jech and 5 more

Open access · goldAbstract read
In one paragraph

Article in Cell reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Clinical, imaging and genetic profile of KMT2B-related dystonia: a review of published cases.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
  3. Dystonia: Insights into Mechanisms and Novel Therapeutics.Current neurology and neuroscience reports · 2026
    Review
  4. Article
  5. Review
  6. Article
  7. Next-generation direct reprogramming.Frontiers in cell and developmental biology · 2024
    Review
  8. Review
  9. Review
  10. Review
  11. Molecular syndromology · 2022
    Article
  12. Reprogramming of the epigenome in neurodevelopmental disorders.Critical reviews in biochemistry and molecular biology · 2022
    Review
  13. Article
  14. Direct cell reprogramming: approaches, mechanisms and progress.Nature reviews. Molecular cell biology · 2021
    Review
  15. Emerging and converging molecular mechanisms in dystonia.Journal of neural transmission (Vienna, Austria : 1996) · 2021
    Review
  16. Article
  17. Genetic Dystonias: Update on Classification and New Genetic Discoveries.Current neurology and neuroscience reports · 2021
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 4 countries.

Giulia BarbagiovanniDepartment of Experimental Oncology, IEO, European Institute of Oncology IRCCS, 20139 Milan, Italy.
Pierre-Luc GermainDepartment of Experimental Oncology, IEO, European Institute of Oncology IRCCS, 20139 Milan, Italy.
Michael ZechInstitut für Neurogenomik, Helmholtz Zentrum München, 85764 Munich, Germany; Klinik und Poliklinik für Neurologie, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany.
Sina AtashpazDepartment of Experimental Oncology, IEO, European Institute of Oncology IRCCS, 20139 Milan, Italy.
Pietro Lo RisoDepartment of Experimental Oncology, IEO, European Institute of Oncology IRCCS, 20139 Milan, Italy.
Agnieszka D'Antonio-ChronowskaDepartment of Experimental Oncology, IEO, European Institute of Oncology IRCCS, 20139 Milan, Italy.
Erika TenderiniDepartment of Experimental Oncology, IEO, European Institute of Oncology IRCCS, 20139 Milan, Italy.
Massimiliano CaiazzoSan Raffaele Scientific Institute, 20132 Milan, Italy.
Sylvia BoeschDepartment of Neurology, Medical University Innsbruck, 6020 Innsbruck, Austria.
Robert JechDepartment of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General Faculty Hospital, 12821 Prague, Czech Republic.
Bernhard HaslingerKlinik und Poliklinik für Neurologie, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany.
Vania BroccoliSan Raffaele Scientific Institute, 20132 Milan, Italy; National Research Council (CNR), Institute of Neuroscience, 20129 Milan, Italy.
Adrian Francis StewartGenomics, Biotechnology Center, Center for Molecular and Cellular Bioengineering, Technische Universität Dresden, 01069 Dresden, Germany.
Juliane WinkelmannInstitut für Neurogenomik, Helmholtz Zentrum München, 85764 Munich, Germany; Lehrstuhl für Neurogenetik und Institut für Humangenetik, Technische Universität München, 81675 Munich, Germany; Munich Cluster for Systems Neurology, SyNergy, 81829 Munich, Germany.
Giuseppe TestaDepartment of Experimental Oncology, IEO, European Institute of Oncology IRCCS, 20139 Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy. Electronic address: giuseppe.testa@ieo.it.
European Institute of Oncology · ITSan Raffaele University of Rome · ITCharles University · CZHelmholtz Zentrum München · DEInnsbruck Medical University · ATKlinik und Poliklinik für Neurologie · DETechnical University of Munich · DETU Dresden · DEUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transdifferentiation of fibroblasts into induced neuronal cells (iNs) by the neuron-specific transcription factors Brn2, Myt1l, and Ascl1 is a paradigmatic example of inter-lineage conversion across epigenetically distant cells. Despite tremendous progress regarding the transcriptional hierarchy underlying transdifferentiation, the enablers of the concomitant epigenome resetting remain to be elucidated. Here, we investigated the role of KMT2A and KMT2B, two histone H3 lysine 4 methylases with cardinal roles in development, through individual and combined inactivation. We found that Kmt2b, whose human homolog's mutations cause dystonia, is selectively required for iN conversion through suppression of the alternative myocyte program and induction of neuronal maturation genes. The identification of KMT2B-vulnerable targets allowed us, in turn, to expose, in a cohort of 225 patients, 45 unique variants in 39 KMT2B targets, which represent promising candidates to dissect the molecular bases of dystonia.

Indexed as

Cell TransdifferentiationGenetic Association StudiesAnimalsCell DifferentiationDystoniaEmbryo, MammalianEpigenesis, GeneticFibroblastsHistone-Lysine N-MethyltransferaseHistonesHumansLysineMethylationMice, KnockoutMyeloid-Lymphoid Leukemia ProteinNeuronsHistone-Lysine N-MethyltransferaseHistonesKmt2a protein, mouseKMT2B protein, humanKmt2d protein, mouseLysineMyeloid-Lymphoid Leukemia Proteincell fate conversiondystoniaepigeneticshistone H3 lysine 4 methylationinduced neuronal cellsKMT2BMLL2mouse embryonic fibroblastsmyocytestransdifferentiation

Identifiers

PMID30355503
PMCPMC6218204
OpenAlexW2897051414

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.